{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:07:20Z","timestamp":1761581240404},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,10,15]],"date-time":"2014-10-15T00:00:00Z","timestamp":1413331200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s11307-014-0800-x","type":"journal-article","created":{"date-parts":[[2014,10,14]],"date-time":"2014-10-14T14:24:11Z","timestamp":1413296651000},"page":"424-433","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["BAY 1075553 PET-CT for Staging and Restaging Prostate Cancer Patients: Comparison with [18F] Fluorocholine PET-CT (Phase I Study)"],"prefix":"10.1007","volume":"17","author":[{"given":"Mohsen","family":"Beheshti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Kunit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silke","family":"Haim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rasoul","family":"Zakavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludger","family":"Dinkelborg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner","family":"Langsteger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Loidl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,10,15]]},"reference":[{"key":"800_CR1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","volume":"59","author":"A Jemal","year":"2009","unstructured":"Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225\u2013249","journal-title":"CA Cancer J Clin"},{"key":"800_CR2","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","volume":"49","author":"J Ferlay","year":"2012","unstructured":"Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al (2012) Cancer incidence and mortality patterns in Europe: estimates for 40 countries. Eur J Cancer 49:1374\u20131403","journal-title":"Eur J Cancer"},{"key":"800_CR3","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nrurol.2009.81","volume":"6","author":"H Jadvar","year":"2009","unstructured":"Jadvar H (2009) Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET. Nat Rev Urol 6:317\u2013323","journal-title":"Nat Rev Urol"},{"key":"800_CR4","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2967\/jnumed.112.110148","volume":"54","author":"M Beheshti","year":"2013","unstructured":"Beheshti M, Haim S, Zakavi R et al (2013) Impact of 18F -choline PET\/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics. J Nucl Med 54:833\u2013840","journal-title":"J Nucl Med"},{"key":"800_CR5","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1148\/radiol.09090413","volume":"254","author":"M Beheshti","year":"2010","unstructured":"Beheshti M, Imamovic L, Broinger G et al (2010) 18F choline PET\/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 254:925\u2013933","journal-title":"Radiology"},{"key":"800_CR6","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s00259-005-1764-5","volume":"32","author":"F Dehdashti","year":"2005","unstructured":"Dehdashti F, Picus J, Michalski JM et al (2005) Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging 32:344\u2013350","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"800_CR7","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1007\/s00259-002-0885-3","volume":"29","author":"T Kato","year":"2002","unstructured":"Kato T, Tsukamoto E, Kuge Y et al (2002) Accumulation of [11C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer. Eur J Nucl Med Mol Imaging 29:1492\u20131495","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"800_CR8","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1148\/radiol.11102023","volume":"259","author":"DM Schuster","year":"2011","unstructured":"Schuster DM, Savir-Baruch B, Nieh PT et al (2011) Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET\/CT and 111In-capromab pendetide SPECT\/CT. Radiology 259:852\u2013861","journal-title":"Radiology"},{"key":"800_CR9","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1053\/j.semnuclmed.2009.05.003","volume":"39","author":"M Beheshti","year":"2009","unstructured":"Beheshti M, Langsteger W, Fogelman I (2009) Prostate cancer: role of SPECT and PET in imaging bone metastases. Semin Nucl Med 39:396\u2013407","journal-title":"Semin Nucl Med"},{"key":"800_CR10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/1078-1439(95)00002-Y","volume":"1","author":"GL Wright Jr","year":"1995","unstructured":"Wright GL Jr, Haley C, Beckett ML, Schellhammer PF (1995) Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol 1:18\u201328","journal-title":"Urol Oncol"},{"key":"800_CR11","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S","volume":"82","author":"DG Bostwick","year":"1998","unstructured":"Bostwick DG, Pacelli A, Blute M et al (1998) Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 82:2256\u20132261","journal-title":"Cancer"},{"key":"800_CR12","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/pros.21241","volume":"71","author":"S Minner","year":"2011","unstructured":"Minner S, Wittmer C, Graefen M et al (2011) High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate 71:281\u2013288","journal-title":"Prostate"},{"key":"800_CR13","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1365-2559.2007.02635.x","volume":"50","author":"P Mhawech-Fauceglia","year":"2007","unstructured":"Mhawech-Fauceglia P, Zhang S, Terracciano L et al (2007) Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using multiple tumour tissue microarray technique. Histopathology 50:472\u2013483","journal-title":"Histopathology"},{"key":"800_CR14","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR et al (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3:81\u201385","journal-title":"Clin Cancer Res"},{"key":"800_CR15","first-page":"3192","volume":"59","author":"SS Chang","year":"1999","unstructured":"Chang SS, Reuter VE, Heston WD et al (1999) Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 59:3192\u20133198","journal-title":"Cancer Res"},{"key":"800_CR16","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.neuroscience.2006.10.022","volume":"144","author":"P Sacha","year":"2007","unstructured":"Sacha P, Zamecnik J, Barinka C et al (2007) Expression of glutamate carboxypeptidase II in human brain. Neuroscience 144:1361\u20131372","journal-title":"Neuroscience"},{"key":"800_CR17","doi-asserted-by":"crossref","first-page":"380","DOI":"10.2967\/jnumed.112.111203","volume":"54","author":"JA Barrett","year":"2013","unstructured":"Barrett JA, Coleman RE, Goldsmith SJ et al (2013) First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer. J Nucl Med 54:380\u2013387","journal-title":"J Nucl Med"},{"key":"800_CR18","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","volume":"40","author":"A Afshar-Oromieh","year":"2013","unstructured":"Afshar-Oromieh A, Malcher A, Eder M et al (2013) PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 40:486\u2013495","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"800_CR19","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/ijc.2910620511","volume":"62","author":"JK Troyer","year":"1995","unstructured":"Troyer JK, Beckett ML, Wright GL Jr (1995) Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 62:552\u2013558","journal-title":"Int J Cancer"},{"key":"800_CR20","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1200\/JCO.2007.15.0532","volume":"26","author":"MD Galsky","year":"2008","unstructured":"Galsky MD, Eisenberger M, Moore-Cooper S et al (2008) Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol 26:2147\u20132154","journal-title":"J Clin Oncol"},{"key":"800_CR21","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2004.09.154","volume":"22","author":"MI Milowsky","year":"2004","unstructured":"Milowsky MI, Nanus DM, Kostakoglu L et al (2004) Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 22:2522\u20132531","journal-title":"J Clin Oncol"},{"issue":"5","key":"800_CR22","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.juro.2013.10.041","volume":"191","author":"JR Osborne","year":"2014","unstructured":"Osborne JR, Green DA, Spratt DE et al (2014) A prospective pilot study of Zr-J591\/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy. J Urol 191(5):1439\u20131445","journal-title":"J Urol"},{"key":"800_CR23","doi-asserted-by":"crossref","first-page":"606","DOI":"10.2967\/jnumed.108.058487","volume":"50","author":"U Elsasser-Beile","year":"2009","unstructured":"Elsasser-Beile U, Reischl G, Wiehr S et al (2009) PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen. J Nucl Med 50:606\u2013611","journal-title":"J Nucl Med"},{"key":"800_CR24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00259-013-2527-3","volume":"41","author":"R Lesche","year":"2014","unstructured":"Lesche R, Kettschau G, Gromov AV et al (2014) Preclinical evaluation of BAY 1075553, a novel (18)F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging 41:89\u2013101","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"800_CR25","first-page":"92","volume":"43","author":"TR DeGrado","year":"2002","unstructured":"DeGrado TR, Reiman RE, Price DT et al (2002) Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med 43:92\u201396","journal-title":"J Nucl Med"},{"key":"800_CR26","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s00259-006-0150-2","volume":"33","author":"M Cimitan","year":"2006","unstructured":"Cimitan M, Bortolus R, Morassut S et al (2006) [(18)F] Fluorocholine PET\/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 33:1387\u20131398","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"800_CR27","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1148\/radiol.2352040494","volume":"235","author":"DT Schmid","year":"2005","unstructured":"Schmid DT, John H, Zweifel R et al (2005) Fluorocholine PET\/CT in patients with prostate cancer: initial experience. Radiology 235:623\u2013628","journal-title":"Radiology"},{"key":"800_CR28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/med.20165","volume":"30","author":"Y Li","year":"2010","unstructured":"Li Y, Cozzi PJ, Russell PJ (2010) Promising tumor-associated antigens for future prostate cancer therapy. Med Res Rev 30:67\u2013101","journal-title":"Med Res Rev"},{"key":"800_CR29","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/hmg\/10.7.657","volume":"10","author":"OP Kallioniemi","year":"2001","unstructured":"Kallioniemi OP, Wagner U, Kononen J, Sauter G (2001) Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 10:657\u2013662","journal-title":"Hum Mol Genet"},{"key":"800_CR30","first-page":"4055","volume":"58","author":"H Liu","year":"1998","unstructured":"Liu H, Rajasekaran AK, Moy P et al (1998) Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 58:4055\u20134060","journal-title":"Cancer Res"},{"key":"800_CR31","first-page":"6357","volume":"9","author":"JS Ross","year":"2003","unstructured":"Ross JS, Sheehan CE, Fisher HA et al (2003) Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 9:6357\u20136362","journal-title":"Clin Cancer Res"},{"key":"800_CR32","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.humpath.2006.11.012","volume":"38","author":"S Perner","year":"2007","unstructured":"Perner S, Hofer MD, Kim R et al (2007) Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 38:696\u2013701","journal-title":"Hum Pathol"},{"key":"800_CR33","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2174\/1568026611313080008","volume":"13","author":"RC Mease","year":"2013","unstructured":"Mease RC, Foss CA, Pomper MG (2013) PET imaging in prostate cancer: focus on prostate-specific membrane antigen. Curr Top Med Chem 13:951\u2013962","journal-title":"Curr Top Med Chem"},{"key":"800_CR34","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/pros.21493","volume":"72","author":"JR Nedrow-Byers","year":"2012","unstructured":"Nedrow-Byers JR, Jabbes M, Jewett C et al (2012) A phosphoramidate-based prostate-specific membrane antigen-targeted SPECT agent. Prostate 72:904\u2013912","journal-title":"Prostate"},{"key":"800_CR35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/2191-219X-2-23","volume":"2","author":"M Schafer","year":"2012","unstructured":"Schafer M, Bauder-Wust U, Leotta K et al (2012) A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer. EJNMMI Res 2:23","journal-title":"EJNMMI Res"},{"key":"800_CR36","doi-asserted-by":"crossref","first-page":"5333","DOI":"10.1021\/jm100623e","volume":"53","author":"SR Banerjee","year":"2008","unstructured":"Banerjee SR, Pullambhatla M, Byun Y et al (2008) 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem 53:5333\u20135341","journal-title":"J Med Chem"},{"key":"800_CR37","doi-asserted-by":"crossref","first-page":"7933","DOI":"10.1021\/jm801055h","volume":"51","author":"Y Chen","year":"2008","unstructured":"Chen Y, Foss CA, Byun Y et al (2008) Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. J Med Chem 51:7933\u20137943","journal-title":"J Med Chem"},{"key":"800_CR38","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1021\/jm800994j","volume":"52","author":"KP Maresca","year":"2009","unstructured":"Maresca KP, Hillier SM, Femia FJ et al (2009) A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J Med Chem 52:347\u2013357","journal-title":"J Med Chem"},{"key":"800_CR39","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.2967\/jnumed.109.066589","volume":"50","author":"SE Lapi","year":"2009","unstructured":"Lapi SE, Wahnishe H, Pham D et al (2009) Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer. J Nucl Med 50:2042\u20132048","journal-title":"J Nucl Med"},{"key":"800_CR40","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1158\/1078-0432.CCR-07-1517","volume":"14","author":"RC Mease","year":"2008","unstructured":"Mease RC, Dusich CL, Foss CA et al (2008) N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-l-cysteine, [18F] DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res 14:3036\u20133043","journal-title":"Clin Cancer Res"},{"key":"800_CR41","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.2967\/jnumed.110.086751","volume":"52","author":"SM Hillier","year":"2011","unstructured":"Hillier SM, Kern AM, Maresca KP et al (2011) 123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy. J Nucl Med 52:1087\u20131093","journal-title":"J Nucl Med"},{"key":"800_CR42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmp.2008.10.001","volume":"25","author":"M Conti","year":"2009","unstructured":"Conti M (2009) State of the art and challenges of time-of-flight PET. Phys Med 25:1\u201311","journal-title":"Phys Med"},{"key":"800_CR43","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.nima.2007.06.038","volume":"580","author":"WW Moses","year":"2007","unstructured":"Moses WW (2007) Recent advances and future advances in time-of-flight PET. Nucl Inst Methods Phys Res A 580:919\u2013924","journal-title":"Nucl Inst Methods Phys Res A"},{"key":"800_CR44","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/pros.20957","volume":"69","author":"HJ Ananias","year":"2009","unstructured":"Ananias HJ, van den Heuvel MC, Helfrich W, de Jong IJ (2009) Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer. Prostate 69:1101\u20131108","journal-title":"Prostate"},{"key":"800_CR45","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1158\/1078-0432.CCR-04-2690","volume":"11","author":"CA Foss","year":"2005","unstructured":"Foss CA, Mease RC, Fan H et al (2005) Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res 11:4022\u20134028","journal-title":"Clin Cancer Res"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-014-0800-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11307-014-0800-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-014-0800-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T20:11:28Z","timestamp":1598386288000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11307-014-0800-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,15]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["800"],"URL":"https:\/\/doi.org\/10.1007\/s11307-014-0800-x","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,15]]}}}